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Abstract
Background: Onset and development of the multifactorial disease age-related macular degeneration (AMD) are highly
interrelated with mitochondrial functions such as energy production and free radical turnover. Mitochondrial dysfunction
and overproduction of reactive oxygen species may contribute to destruction of the retinal pigment epithelium, retinal
atrophy and choroidal neovascularization, leading to AMD. Consequently, polymorphisms of the mitochondrial genome
(mtDNA) are postulated to be susceptibility factors for this disease. Previous studies from Australia and the United States
detected associations of mitochondrial haplogroups with AMD. The aim of the present study was to test these associations
in Middle European Caucasians.
Methodology/Principal Findings: Mitochondrial haplogroups (combinations of mtDNA polymorphisms) and mitochondrial
CR polymorphisms were analyzed in 200 patients with wet AMD (choroidal neovascularization, CNV), in 66 patients with dry
AMD, and in 385 controls from Austria by means of multiplex primer extension analysis and sequencing, respectively. In
patients with CNV, haplogroup H was found to be significantly less frequent compared to controls, and haplogroup J
showed a trend toward a higher frequency compared to controls. Five CR polymorphisms were found to differ significantly
in the two study populations compared to controls, and all, except one (T152C), are linked to those haplogroups.
Conclusions/Significance: It can be concluded that haplogroup J is a risk factor for AMD, whereas haplogroup H seems to
be protective for AMD.
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Introduction
In the western world, age-related macular degeneration (AMD)
is the most frequent cause of visual loss in people aged 50 or older
[1]. The incidence of AMD is low in persons younger than 50
years (0.05%), but climbs to 11.8% in persons over the age of 80
[2]. AMD affects the macula, a retinal region containing the
highest density of photoreceptors and generating central high-
resolution visual acuity. In AMD, the presence of so-called drusen,
deposits of acellular debris in between the retinal pigment
epithelium and the Bruch’s membrane, localized posterior to the
photoreceptors, is the first characteristic sign of the disease. A few
small drusen may appear in the retina of individuals over 50 years
of age without relation to AMD. An excess of drusen and/or
medium sized or large drusen, however, may lead to destruction of
the retinal pigment epithelium and, in combination with
inflammatory processes, cause atrophy of the retina and mild
visual impairment. Subsequent retinal atrophy reaching further
into the center of the macula (dry AMD), and also choroidal
neovascularization (CNV, wet AMD) with augmented vascular
permeability and fragility resulting in retinal edema and/or
hemorrhage, may cause visual loss [1].
AMD is a multifactorial disease, where several risk factors and
genetic variants may act together, resulting in disease development.
Besides age, known risk factors are amongst others smoking and
white race [1]. Nuclear encoded genetic susceptibility factors for
AMD include the polymorphism Tyr402His in the complement
factor H (CFH) gene, as well as the Ala69Ser polymorphism in the
age-related maculopathy susceptibility 2 gene (ARMS2) [1,3,4].
The retinal pigment epithelium, being metabolically very active,
comprises a high number of mitochondria [5]. In a process called
oxidative phosphorylation (OXPHOS), these organelles produce
most of the cellular energy in the form of ATP, as well as reactive
oxygen species (ROS). Thirteen subunits of the OXPHOS enzymes
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including those produced in mitochondria by the electron transport
chain, preferentially damage mtDNA. In turn, damaged mtDNA
induces mitochondrial dysfunction with disturbed OXPHOS and
higher production of ROS, initiating a vicious circle [7].
The retinal pigment epithelium is especially susceptible to
mitochondrial dysfunction and ROS damage and, being a post-
mitotic tissue, does not regenerate, and thus accumulates mtDNA
somatic mutations [8,9]. A higher prevalence of AMD in older
people and the progressive nature of the disease, as well as the high
susceptibility of the retina to oxidative stress, hint at mitochondrial
involvement in the progress of AMD.
Interestingly, some patients suffering from mitochondrial
diseases caused by mutations or deletions of mtDNA, such as
Leber’s hereditary optic neuropathy (LHON) or Kearns-Sayre
syndrome, have been shown to exhibit retinal pigmentary changes
resembling features of the early AMD phenotype [10,11].
Neutral polymorphisms of mtDNA or combinations of these,
defined as mtDNA haplogroups, might also contribute to AMD
onset or progression. Mitochondrial haplogroups (H, J, U and T)
and polymorphisms (73, 4917 and 16126, among others) have
already been detected to be associated with AMD in case-control
studies from the United States (US) and Australia [12–15]. In
epidemiological studies it is important to obtain repetitive results in
different studies and different geographical regions. This is of high
relevance for interpretation of such data, in order to avoid the
influence of possible confounding factors that might bias the result
of one particular study. In studies analyzing mtDNA, repetitive
results are even more crucial, as haplogroup distributions can vary
between populations within only small regional distances [16].
Hence, the aim of the present study was to confirm associations
between mtDNA haplogroups and AMD that were obtained in
US and Australian populations, in Middle-European Caucasians.
Results
Mitochondrial haplogroups H and J are associated with
CNV
In the present case-control study, haplogroups and polymor-
phisms of the non-coding CR of mtDNA were analyzed in patients
with wet AMD (CNV) and dry AMD and compared to those in
controls. Clinical characteristics of the study groups are presented
in Table 1.
The frequencies of mitochondrial haplogroups and CR poly-
morphisms in the control group were very similar to those
previously reported in a large control group from Salzburg [17–20].
In patients with CNV, haplogroup H was found at a
significantly lower frequency than in the control group [36.0%
vs. 44.9%, p=0.038, OR 0.69 (0.5–1.0); after adjustment for age
and sex: p=0.035, OR 0.68 (0.5–1.0)] (Table 2).
Table 1. Characteristics of the study populations.
Patients with CNV
a Patients with dry AMD
b Control group
n=200 n=66 n=385
Mean (SD
c) age (years) at diagnosis 77.2 (8.4) 80.9 (6.0) 73.6 (9.5)
Male (%) 34.0 42.4 49.9
aCNV=choroidal neovascularization.
bAMD=age-related macular degeneration.
cSD=standard deviation.
doi:10.1371/journal.pone.0030874.t001
Table 2. Frequencies (%) of mitochondrial haplogroups in
Caucasian patients with CNV and in controls.
Patients with CNV
a Control group P-value
b
n=200 n=385
H 36.0 44.9 0.038
U 18.0 15.9 0.506
J 15.0 9.6 0.052
T 10.5 7.5 0.223
K 5.5 3.9 0.372
W 0.5 2.3 0.176
V 2.0 3.4 0.347
I 2.0 0.8 0.238
X 2.0 1.6 0.742
Others
c 8.5 10.1 0.525
aCNV=choroidal neovascularization.
bP-value: Pearson chi-square or Fisher’s exact test.
cHaplogroups that could not be assigned to one of the nine major European
haplogroups by the SNP combination.
doi:10.1371/journal.pone.0030874.t002
Table 3. Frequencies (%) of mitochondrial haplogroups in
Caucasian patients with dry AMD and in controls.
Patients with dry AMD
a Control group P-value
b
n=66 n=385
H 48.5 44.9 0.593
U 13.6 15.9 0.647
J 7.6 9.6 0.599
T 9.1 7.5 0.662
K 3.0 3.9 1.000
W 6.1 2.3 0.107
V 3.0 3.4 1.000
I 0.0 0.8 1.000
X 4.5 1.6 0.131
Others
c 4.6 10.1 0.149
aAMD=age-related macular degeneration.
bP-value: Pearson chi-square or Fisher’s exact test.
cHaplogroups that could not be assigned to one of the nine major European
haplogroups by the SNP combination.
doi:10.1371/journal.pone.0030874.t003
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CNV compared to the control group [15.0% vs. 9.6%, p=0.052,
OR 1.66 (1.0–2.8); after adjustment for age and sex: p=0.048,
OR 1.72 (1.0–2.9)] (Table 2).
When haplogroup frequencies were compared between patients
with dry AMD and the controls, no significant differences were
found (Table 3).
Age-related macular degeneration and mitochondrial CR
polymorphisms
The mitochondrial CR was sequenced and analyzed between
nucleotide position 16038 and 569. All polymorphisms and their
frequencies and the results of comparisons between patients with
CNV and controls as well as between patients with dry AMD and
controls are listed in Table S1 and Table S2, respectively. CR
polymorphisms with a frequency higher than 5% are listed in
Table 4 and Table 5. The CR polymorphism T152C was found to
be present at a significantly higher frequency in patients with CNV
compared to controls. An additional four CR polymorphisms were
significantly more frequent in patients with CNV compared to
controls (Table 4). However, three of these are linked to
mitochondrial haplogroup J [C16069T (J), T16126C (JT), C295T
(J)] [21]. The mtDNA CR position 73A defines the macro-
haplogroup R0, including its predominant subclade haplogroup H
aswellashaplogroup V [21,22].TheCRpolymorphism A73G,was
found to have a significantly higher frequency in CNV patients
compared to controls. Because of the inverse correlation of A73G to
haplogroup H, the results of the mitochondrial CR polymorphism
analysis are consistent with the results of mitochondrial haplogroup
frequencies.
Table 4. Frequencies (%) of control region polymorphisms .5% in patients with CNV and in controls as well as the corresponding
odds ratios and 95% confidence intervals.
Polymorphism in mtDNA
a
control region
Frequency in patients
with CNV
b
n
c
Frequency in
control group n
c P-value
d
Odds ratio
(95% CI
e)P - v a l u e
f
aOdds ratio
(95% CI
e)
f
n=200 n=385
C16069T 16.00 32 10.13 39 0.039 1.69 (1.0–2.8) 0.038 1.74 (1.0–2.9)
T16093C 9.00 18 8.31 32 0.778
T16126C 28.50 57 18.70 72 0.007 1.73 (1.2–2.6) 0.006 1.79 (1.2–2.7)
T16189C 14.00 28 11.17 43 0.320
C16223T 6.50 13 7.01 27 0.816
C16270T 9.50 19 5.71 22 0.089
C16294T 11.50 23 9.61 37 0.475
C16296T 6.00 12 6.49 25 0.816
T16304C 8.50 17 9.87 38 0.590
T16311C 14.00 28 9.87 38 0.134
T16356C 5.50 11 7.27 28 0.415
T16362C 7.50 15 6.49 25 0.647
T16519C 63.00 126 65.45 252 0.556
A73G 62.50 125 51.43 198 0.011 1.57 (1.1–2.2) 0.012 1.58 (1.1–2.3)
T146C 12.50 25 8.05 31 0.083
C150T 12.50 25 10.13 39 0.384
T152C 28.50 57 20.78 80 0.036 1.52 (1.0–2.3) 0.014 1.67 (1.1–2.5)
G185A 8.00 16 5.71 22 0.287
T195C 18.50 37 17.92 69 0.863
G228A 8.50 17 5.97 23 0.251
A263G 98.50 197 98.44 379 1.000
C295T 16.50 33 10.39 40 0.034 1.70 (1.0–2.8) 0.035 1.74 (1.0–2.9)
A302InsC 43.50 87 36.62 141 0.106
A302InsCC 9.00 18 13.25 51 0.131
T310InsC 94.50 189 94.03 362 0.816
C462T 11.00 22 6.75 26 0.076
T489C 16.50 33 10.91 42 0.055
CA514/515Del 10.50 21 10.13 39 0.889
amtDNA=mitochondrial DNA.
bCNV=choroidal neovascularisation.
cn: number of individuals with the respective polymorphism.
dP-value: Pearson chi-square or Fisher’s exact test.
eCI=confidence interval.
fadjusted for age and sex by logistic regression analysis.
doi:10.1371/journal.pone.0030874.t004
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higher than 5% in both controls and patients with dry AMD. Of
these, T195C had a significantly higher frequency in patients with
dry AMD compared to controls [33.3% vs. 17.9%, p,0.005, OR
2.29 (1.3–4.1); after adjustment for age and sex: p,0.01, OR 2.30
(1.3–4.2)] (Table 5).
Discussion
Studies have shown that oxidative stress plays a causative role in
the pathogenesis of AMD, and that mitochondria are instrumental
in this etiology. For example, Imamura et al. observed in the
retinas of Sod1
2/2 mice, which lack the antioxidant enzyme Cu,
Zn-superoxide dismutase (SOD1), elevated levels of oxidative
damage to DNA and protein as well as development of drusen and
CNV with age, signs shared by human AMD [23]. Vives-Bauza et
al. reported that a combination of mild OXPHOS defects, caused
by the mtDNA T8993G point mutation, together with low levels
of the autofluorescent constituent of lipofuscin, A2E, induced a
reduction in the phagocytic competence of the retinal pigment
epithelium. The combination of low levels of A2E and more severe
OXPHOS defects induced retinal pigment epithelium cell death
[9]. All these facts support the conclusion that mtDNA variation
contributes to the complex etiology of AMD.
Accordingly, in the present study we observed a higher
prevalence of mitochondrial haplogroup J and a significantly
lower prevalence of haplogroup H in patients with CNV
compared to the control group. That the CR polymorphisms
linked to haplogroups J and H also showed positive and negative
associations, respectively, with CNV further supports the hap-
logroup–CNV association.
The CR polymorphism T152C, although it is not associated
with any particular haplogroup, was also present at a higher
frequency in patients with CNV compared to controls. For dry
AMD, only one significant association was found, namely a higher
frequency of T195C in patients compared to controls. The study
group of patients with dry AMD (n=66) was small, and also no
data were available according to a classification into early,
intermediate or advanced AMD. Hence, these results should be
considered tentative. Associations of T152C and T195C have
Table 5. Frequencies (%) of control region polymorphisms .5% in patients with dry AMD and in controls.
Polymorphism in mtDNA
a control region Frequency in patients with dry AMD
b
n
c
Frequency in
control group n
c P-value
d
n=66 n=385
C16069T 9.09 6 10.13 39 0.795
T16093C 7.58 5 8.31 32 0.840
T16126C 16.67 11 18.70 72 0.694
T16189C 13.64 9 11.17 43 0.562
C16223T 12.12 8 7.01 27 0.152
C16294T 9.09 6 9.61 37 0.894
T16298C 6.06 4 5.97 23 1.000
T16304C 9.09 6 9.87 38 0.844
T16311C 12.12 8 9.87 38 0.577
T16356C 7.58 5 7.27 28 1.000
T16362C 6.06 4 6.49 25 1.000
T16519C 75.76 50 65.45 252 0.100
A73G 54.55 36 51.43 198 0.640
T146C 7.58 5 8.05 31 0.895
C150T 12.12 8 10.13 39 0.625
T152C 24.24 16 20.78 80 0.525
T195C 33.33 22 17.92 69 0.004
A263G 100.00 66 98.44 379 0.599
C295T 7.58 5 10.39 40 0.481
A302InsC 30.30 20 36.62 141 0.322
A302InsCC 10.61 7 13.25 51 0.554
T310InsC 93.94 62 94.03 362 1.000
T489C 7.58 5 10.91 42 0.413
G499A 7.58 5 6.23 24 0.596
G513InsCA 6.06 4 5.97 23 1.000
CA514/515Del 7.58 5 10.13 39 0.518
amtDNA=mitochondrial DNA.
bAMD=age-related macular degeneration.
cn: number of individuals with the respective polymorphism.
dP-value: Pearson chi-square or Fisher’s exact test.
doi:10.1371/journal.pone.0030874.t005
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weak protective effect) [24] and with early childhood bronchitis
(T195C – increased risk) [25]. The mitochondrial CR polymor-
phisms T152C and T195C are mutational hotspots [21,26], and
are found on the background of several haplogroups.
Lack of Bonferroni correction might be considered to be a
limitation of the present study. However, we believe that
Bonferroni correction is not the adequate method for our type
of analysis, because our study was intended to be a confirmation
study and because CR polymorphisms that showed significantly
different frequencies between controls and patients are strongly
linked to haplogroups H and J.
Jones et al. compared mtDNA haplogroup frequencies in 317
patients with AMD to those of 2985 controls from Australia. After
adjustment for age, sex and smoking they found haplogroup H to be
at a reduced prevalence in the AMD group compared to controls,
very similar to the results obtained in the present study (Table 6).
Additionally,subjects with haplogroup J were found to have a higher
risk of developing large, soft, distinct drusen [12]. Unfortunately, in
our study no data concerning drusen development were available.
In 560 Caucasians from the US, Canter et al. detected the
mitochondrial haplogroup T-linked polymorphism A4917G to be
significantly associated with AMD (Table 6) [13]. In our study,
we were not able to find a significant association with this
polymorphism, although we did observe a tendency toward a
higher frequency of A4917G (11.5% vs. 8.3%, data not shown) as
well as of mitochondrial haplogroup T (10.5% vs. 7.5%) in
patients with CNV compared to controls (Table 2 and Table 6).
A4917G and the CR polymorphisms C16069T and T16126C,
which are linked to haplogroup J (C16069T) and the haplogroup
cluster JT (T16126C), were found to be associated with AMD in a
case-control study (73 controls and 81 patients) from the US
(Table 6) [14]. Moreover, SanGiovanni et al. found a significant
association of A4917G and the CR positions 73A and T16126C
with advanced AMD in 314 (215 cases and 99 controls) non-
Hispanic US and Australian subjects (Table 6) [15].
Our study adds to these previous studies from the US and
Australia in providing corroborative data for a population from a
geographically well-defined and distinct region of Middle Europe.
Combining all the results, the conclusion can be drawn that
mtDNA haplogroups J and T are risk factors, and that mtDNA
haplogroup H is a protective factor, for AMD in Caucasian
populations.
Methods
Ethics Statement
Before entering the study, subjects gave written informed
consent, and anonymity of the patients was assured. The study was
performed in accordance with the National Gene Technology Act
of Austria and followed the Declaration of Helsinki. The study was
approved by the Local Province of Salzburg Ethics Committee
(‘‘Ethikkommission fu ¨r das Bundesland Salzburg; Amt der
Salzburger Landesregierung, Abteilung 9 Gesundheit und Sport’’).
Patients and control subjects
In this case-control study we included a total of 651 Caucasian
subjects. All participants were enrolled in the Department of
Ophthalmology, University Hospital Salzburg, Paracelsus Medical
University. Blood samples from patients and controls were collected
from August 2006 to October 2008. Recruitment of patients and
controls was done as follows. Each patient diagnosed for CNV was
asked if he agreed to participate in the study. Controls were mainly
subjects who were kept as an inpatient for cataract surgery. Here,
subjects were asked for agreement sporadically. Patients with dry
AMD were also recruited sporadically. Sixty-six patients were
diagnosed with dry AMD, 200 patients with CNV, and a control
group of 385 subjects did not show any signs of AMD (i.e. no
Table 6. Comparison of age-related macular degeneration case-control studies in the literature with the present study.
MtDNA
a haplogroup
or polymorphism Haplogroup
b Frequency (%) in cases Frequency (%) in controls P-value
c Odds ratio (95% CI
d) References
H 37.5 43.5 not shown 0.75 (0.6–1.0) [12]
36.0 44.9 0.035 0.68 (0.5–1.0) Present study
4917G T 15.4 9.0 0.011 2.16 (1.2–3.9) [13]
12.2 2.7 0.020 5.00 (1.1–23.6) [14]
16.3 4.0 0.001 6.15 (2.0–18.5) [15]
11.5 8.3 0.143 1.54 (0.9–2.8) Present study
T 10.5 7.5 0.133 1.59 (0.9–2.9) Present study
73G non-HV,H,V 62.5 51.4 0.012 1.58 (1.1–2.3) Present study
73A HV,H,V 35.8 48.5 0.030 0.58 (0.4–1.0) [15]
16069T J 9.9 4.1 0.055 3.89 (0.8–19.0) [14]
16.0 10.1 0.038 1.74 (1.0–2.9) Present study
16126C JT 24.7 8.2 0.004 3.66 (1.4–9.7) [14]
27.0 13.1 0.007 2.51 (1.3–4.9) [15]
28.5 18.7 0.006 1.79 (1.2–2.7) Present study
amtDNA=mitochondrial DNA.
bAccording to PhyloTree.org [21].
cP-values: present study: adjusted for age and sex. Jones et al. [12]: adjusted for age, sex and current smoking. Canter et al. [13]: adjusted for sex and three nuclear
polymorphisms (CFH-Complement Factor H gene, rs1061170; LOC387715, rs10490924; APOE, ApoE2 allele). Udar et al. [14]: no adjustment. SanGiovanni et al. [15]:
adjusted for age, sex and smoking.
dCI=confidence interval.
doi:10.1371/journal.pone.0030874.t006
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secondary CNV resulting from myopia, inflammatory or infectious
chorioretinitis, angioid streaks, hereditary diseases or trauma were
not included in the present study.
In all participants a complete ophthalmological examination,
including dilated fundus examination, was performed. Distance
visual acuity was measured at a distance of 4 m using Snellen charts.
When CNV was suspected, additionally fundus photography,
fluorescein angiography and optical coherence tomography (OCT)
were conducted. Fundus photography and fluorescence angiograms
were obtained digitally with a Zeiss fundus camera and imaging
software (FODAS), and central macular thickness was measured
with a Zeiss-Humphrey OCT Stratus 3000 (Jena, Germany).
Mitochondrial DNA analysis
Mitochondrial haplogroups were assessed as described before
[27]. Haplogroups that could not be assigned to one of the nine
major European haplogroups by their single nucleotide polymor-
phism (SNP) combination were designated as ‘‘others’’.
CR sequences were analyzed between nucleotide positions
16038 and 569. Polymerase chain reaction and sequencing was
performed as described previously [27]; however, the primer
15997f: 59-CACCATTAGCACCCAAAGCT-39 was used instead
of 16098f.
Statistical analysis
Frequencies of all mitochondrial haplogroups and CR poly-
morphisms were tested for independence for the disease using
Pearson chi-square statistics and Fisher’s exact test as appropriate.
Only haplogroups and polymorphisms with a frequency higher
than 5% in both study groups were subjected to further statistical
analysis. Associations were adjusted for age and sex using logistic
regression analysis. A p-value ,0.05 was considered statistically
significant. All analyses were performed using PASW statistics 18.0
(SPSS GmbH, Germany).
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